EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Off‐Label Use of Selective JAK1 Inhibitors in Immune‐Mediated Inflammatory Skin Diseases: A Retrospective Case Series

Si Zhang, Xinnuo Chen, Maoying Li, Xi Wang, Cuihong Lian

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/1600487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 26.05.2026. Verfasst von Si Zhang und 4 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article aimed to evaluate the efficacy and safety of JAK1 inhibitors (abrocitinib and upadacitinib) in off‐label treatment of refractory inflammatory skin diseases. We retrospectively analyzed 19 patients with various immune‐mediated dermatoses, including cutaneous lichen planus, parapsoriasis, vitiligo, autoimmune bullous diseases, hypereosinophilic dermatitis, cholinergic urticaria, and vasculitis. Patients received oral abrocitinib or upadacitinib, and the dosage was adjusted according to clinical response. Results showed that most patients achieved significant improvement. Adverse events were mild and infrequent, including folliculitis, gastric discomfort, transient thrombocytopenia, and elevated transaminases, which resolved spontaneously or after dose adjustment/withdrawal. These findings suggest that JAK1 inhibitors may be effective and well‐tolerated in managing refractory off‐label ISDs. However, given the limited evidence from case series, cautious risk‐benefit assessment is warranted in clinical practice.

Zitieren

APA

Zhang, S., Chen, X., Li, M., Wang, X., & Lian, C. (2026). Off‐Label Use of Selective JAK1 Inhibitors in Immune‐Mediated Inflammatory Skin Diseases: A Retrospective Case Series. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1600487

Vancouver

Zhang S, Chen X, Li M, Wang X, Lian C. Off‐Label Use of Selective JAK1 Inhibitors in Immune‐Mediated Inflammatory Skin Diseases: A Retrospective Case Series. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1600487

BibTeX
@article{Zhang2026,
  author = {Zhang, Si and Chen, Xinnuo and Li, Maoying and Wang, Xi and Lian, Cuihong},
  title = {Off‐Label Use of Selective JAK1 Inhibitors in Immune‐Mediated Inflammatory Skin Diseases: A Retrospective Case Series},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/1600487}
}
Kostenlos starten →